<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The DNA methylation inhibitor <z:chebi fb="0" ids="50131">5-Aza-2'-deoxycytidine</z:chebi> (5-Aza-CdR) has significant therapeutic value for the treatment of patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>) </plain></SENT>
<SENT sid="1" pm="."><plain>The demethylating effect of 5-Aza-CdR has been well characterized </plain></SENT>
<SENT sid="2" pm="."><plain>In contrast, less is known about the molecular events downstream of the methylation inhibition </plain></SENT>
<SENT sid="3" pm="."><plain>Here, 5-Aza-CdR induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> cells (both p53 mutant and <z:mp ids='MP_0002169'>wild-type</z:mp>) but not in epithelial or <z:mpath ids='MPATH_458'>normal</z:mpath> PBMCs </plain></SENT>
<SENT sid="4" pm="."><plain>Cell <z:hpo ids='HP_0011420'>death</z:hpo> was accompanied by activation of the <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> <z:mpath ids='MPATH_3'>apoptosis</z:mpath> pathway, as shown by release of <z:chebi fb="1" ids="18070">cytochrome c</z:chebi> and AIF and loss of <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> membrane potential (DeltaPsim) </plain></SENT>
<SENT sid="5" pm="."><plain>Activation of caspase-3 (but not -6 and -8) was detectable using Western blot analysis and measurement of caspase enzymatic activity </plain></SENT>
<SENT sid="6" pm="."><plain>5-Aza-CdR treatment resulted in the induction of p21, which correlated with the arrest of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> cells in the G1 cell cycle phase </plain></SENT>
<SENT sid="7" pm="."><plain>Induction of p21 expression was independent of its promoter methylation status but mediated by 5-Aza-CdR-induced reexpression of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-suppressor p73, a known upstream regulator of p21 </plain></SENT>
<SENT sid="8" pm="."><plain>The p73 promoter was hypermethylated in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> cell lines and in primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> cells but not in epithelial cells, which were resistant toward 5-Aza-CdR </plain></SENT>
<SENT sid="9" pm="."><plain>Therefore, 5-Aza-CdR-mediated specific killing of myeloid cells might be dependent on its ability to revert p73 promoter methylation and to reexpress p73 <z:chebi fb="2" ids="33699">mRNA</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>In addition, exogenous expression of p73 rendered epithelial cells sensitive to <z:mpath ids='MPATH_3'>apoptosis</z:mpath> induced by 5-Aza-CdR or other <z:chebi fb="0" ids="35610">cytostatic</z:chebi> drugs </plain></SENT>
<SENT sid="11" pm="."><plain>We therefore conclude that p73 is a relevant target for methylation-dependent efficacy of 5-Aza-CdR in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> cells </plain></SENT>
</text></document>